New 'Armored' immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07368270
Summary
This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults whose diffuse large B-cell lymphoma has come back or not responded to other treatments. The therapy uses the patient's own modified immune cells, which are engineered to target the cancer and potentially overcome some of its defenses. Researchers will enroll about 30 participants to monitor for side effects and see if the treatment shows signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.